Cargando…
EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
Advanced therapy medicinal products (ATMPs) require evaluation by the European Medicines Agency’s Committee for Advanced Therapies prior to being placed on the European market, subject to a Marketing Authorisation granted by the European Commission. In common with other medicinal products, various r...
Autores principales: | Detela, Giulia, Lodge, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378853/ https://www.ncbi.nlm.nih.gov/pubmed/30815512 http://dx.doi.org/10.1016/j.omtm.2019.01.010 |
Ejemplares similares
-
The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021) -
Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
por: Xie, Jinping, et al.
Publicado: (2023) -
Surgery Versus ATMPs: An Example From Ophthalmology
por: Magrelli, Federica M., et al.
Publicado: (2020) -
Foods, Nutrients and Food Ingredients with Authorised EU Health Claims
por: Sadler, Michele
Publicado: (2014) -
A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations
por: Salazar-Fontana, Laura I.
Publicado: (2022)